AIM: £2.88 (+0.03) | Nasdaq: $18.91 (+0.71)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Main Products
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
Innovation Platform
Overview
R&D Approach
Our Pipeline
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Main Products
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Financial Results
Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26
SANET-ep Results
Audio Webcast on Surufatinib Trial Results
Watch presentation
FY2019 Interim Results
Announcement and Presentation webcast
View Event Details
CNBC Squawk Box
CEO Christian Hogg discusses savolitinib and fruquintinib progress
Watch Interview
Fruquintinib in JAMA
Full text of FRESCO colorectal cancer trial published
Read Abstract
Royal Society of Medicine
CEO Christian Hogg speaks at
RSM Medical Innovations Summit
Watch Presentation
AstraZeneca & Chi-Med
Harnessing the power of Chinese scientific innovation
Learn More
Latest News
Innovation Platform
|
10 Oct 2019
Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors
Innovation Platform
|
4 Oct 2019
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma
Group
|
30 Sep 2019
CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term
Group
|
30 Sep 2019
CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term
Innovation Platform
|
29 Sep 2019
Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting
Current Share Price
London AIM:HCM
£2.88
+0.03 | 16 Oct 2019 | 10:46
Nasdaq AIM:HCM
US$18.91
+0.71 | 16 Oct 2019 | 16:00
Note: 1 Nasdaq share = 5 AIM shares
Latest Presentations
30 Sep 2019
Chi-Med Investors Update
29 Sep 2019
ESMO 2019: Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic NETs
21 Sep 2019
CSCO 2019: Association Between Hand-Foot Skin Reaction (HFSR) and Survival Benefit of Fruquintinib in FRESCO Trial
19 Sep 2019
CSCO 2019 : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis
Latest Reports
Interim Report 2019
EN
Annual Report 2018 (with Form 20-F)
EN
Interim Report 2018
EN
Share conversions between AIM & Nasdaq
Mailing list sign-up
Analyst Coverage
Canaccord Genuity
Deutsche Bank
Edison
HSBC
Macquarie
Panmure Gordon
Trinity Delta
The leading China-based innovator
Our
Innovation Platform
focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More
A powerful commercial network in China
Our
Commercial Platform
manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More